MARKET

ONTX

ONTX

Onconova
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2660
+0.0071
+2.74%
After Hours: 0.2680 +0.002 +0.75% 19:33 11/25 EST
OPEN
0.2560
PREV CLOSE
0.2589
HIGH
0.2690
LOW
0.2550
VOLUME
5.89M
TURNOVER
--
52 WEEK HIGH
1.560
52 WEEK LOW
0.1027
MARKET CAP
49.20M
P/E (TTM)
-1.0423
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Onconova Therapeutics Files Investigational New Drug Application for Multi-kinase CDK4/6 Inhibitor ON 123300
U.S. Phase 1 trial patient enrollment to begin in the first half of 2021 China Phase 1 trial enrollment ongoing Key regulatory milestone achieved to enable further study of product candidate for patients with HR+
Benzinga · 3d ago
Onconova Therapeutics Q3 EPS $(0.03), Inline, Sales $66.00K Miss $1.39M Estimate
Onconova Therapeutics (NASDAQ:ONTX) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 96 percent increase over losses of $(0.75) per share from the same period last year.
Benzinga · 11/12 21:26
Onconova Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Onconova Therapeutics, Inc.
ACCESSWIRE · 11/12 19:30
Looking Into Onconova Therapeutics's Return On Capital Employed
During Q2, Onconova Therapeutics's (NASDAQ: ONTX) reported sales totaled $56.00 thousand. Despite a 43.2% in earnings, the company posted a loss of $7.34 million. In Q1, Onconova Therapeutics brought in $52.00 thousand in sales but lost $5.12 million in earnings.What Is Return On Capital Employed
Benzinga · 09/21 15:08
Onconova' partner HanX launches early-stage study of ON 123300 in China
Onconova Therapeutics (ONTX) soars ~28% in premarket, on the heels of initiation of a Phase 1 trial in China for it anti-cancer agent, ON 123300 by its partner, HanX Biopharmaceuticals.In December 2017, Onconova entered into an
Seekingalpha · 09/21 12:34
Onconova Therapeutics Announces Initiation Of Phase 1 Clinical Trial Of ON 123300 In China By Partner HanX Biopharmaceuticals; Co Says Remains On Track To File U.S. IND In Q4 2020 With Phase 1 Set For Q1 2021
Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals Company remains on track to file a US IND in Q4 2020, with commencement of a US
Benzinga · 09/21 12:12
Onconova Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ON 123300 in China by Partner HanX Biopharmaceuticals
Company remains on track to file a US IND in Q4 2020, with commencement of a US Phase 1 study targeted for Q1 2021NEWTOWN, Pa., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer
GlobeNewswire · 09/21 12:00
Onconova Therapeutics Announces Participation at Upcoming Virtual Events
NEWTOWN, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company plans to participate in several upcoming events: * Marcus Evans Healthcare
GlobeNewswire · 09/09 12:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ONTX. Analyze the recent business situations of Onconova through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ONTX stock price target is 0.3000 with a high estimate of 0.3000 and a low estimate of 0.3000.
EPS
Institutional Holdings
Institutions: 51
Institutional Holdings: 13.29M
% Owned: 7.18%
Shares Outstanding: 184.95M
TypeInstitutionsShares
Increased
13
2.53M
New
17
-1.03M
Decreased
3
146.24K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.02%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Director
James Marino
President/Chief Executive Officer/Director
Steven Fruchtman
Chief Financial Officer
Mark Guerin
Senior Vice President
Manoj Maniar
Vice President/General Counsel
Abraham Oler
Director
Henry Bienen
Director
Jerome Groopman
Director
Viren Mehta
Director
Terri Shoemaker
Director
Jack Stover
Director
Anne VanLent
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ONTX
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Onconova Therapeutics Inc stock information, including NASDAQ:ONTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ONTX stock methods without spending real money on the virtual paper trading platform.